jnj 54175446
Small moleculeexperimental
Clinical trial activity
7 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2015 (NCT02475148)
Timeline
Indications
Mechanism of action
- P2X purinoceptor 7ANTAGONIST
P2RX7 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- jnj 54175446
- jnj 54175446
- jnj-54175446
- jnj-54175446
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04116606 | Phase 2 | Sep 12, 2019 | Janssen Pharmaceutica NV, University of Cambridge |
| NCT03058419 | Phase 1 | Mar 14, 2017 | Johnson and Johnson |
| NCT02902601 | Phase 1 | Oct 17, 2016 | Johnson and Johnson |
| NCT02930694 | Phase 1 | Oct 1, 2016 | Johnson and Johnson |
| NCT02933762 | Phase 1 | Sep 1, 2016 | Johnson and Johnson |
| NCT02515955 | Phase 1 | Aug 1, 2015 | Johnson and Johnson |
| NCT02475148 | Phase 1 | Jun 1, 2015 | Johnson and Johnson |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johnson and Johnson | For profit | 6 | 6 | 1 | 2015 |
| Janssen Pharmaceutica NV | For profit | 1 | 0 | 1 | 2019 |
| University of Cambridge | Academic/Hospital | 1 | 1 | 1 | 2019 |
3 organizations
Page 1 / 1